EUCTR2021-002146-33-Outside-EU/EEA进行中（未招募）1 期
Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine when Administered Concomitantly with Routine Pediatric Vaccines in Healthy Toddlers and Infants
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Toddlers and infants:
- •- Participant and parent/guardian are able to attend all scheduled visits and to comply with all study procedures
- •- Born at full term of pregnancy (= 37 weeks) and/or with a birth weight = 5.5 lbs or 2.5 kg
- •Specifically for toddlers:
- •- Aged 12 to 15 months on the day of the first study visit
- •- Participant has received 3 doses of Prevnar 13 and 3 doses of diphteria, tetanus, acellular pertussis, poliovirus and Haemophilus influenzae type b antigens in infancy
- •Specifically for infants:
- •- Aged 42 to 89 days on the day of the first study visit
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 840
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Participants are excluded from the study if any of the following criteria apply:
- •Toddlers and infants
- •- Participation at the time of study enrollment (or in the 4 weeks preceding the first study vaccination) or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure
- •- Family history of congenital or hereditary immunodeficiency, until the immune competence of the potential vaccine recipient is demonstrated
- •- Blood dyscrasias, leukemia, lymphoma of any type, or other malignant neoplasms affecting the bone marrow or lymphatic systems
- •- Active tuberculosis
- •- History of S. pneumoniae infection or disease, confirmed either serologically or microbiologically
- •- History of any neurologic disorder, including any seizures and progressive neurologic disorders
- •- History of Guillain-Barré syndrome
- •- Known systemic hypersensitivity to any of the vaccine components or to latex, or history of a life-threatening reaction to the vaccines used in the study or to a vaccine containing any of the same substances
- •- Verbal report of thrombocytopenia contraindicating intramuscular vaccination in the Investigator’s opinion
- •- Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular vaccination in the Investigator's opinion
- •- Receipt of oral or injectable antibiotic therapy within 72 hours prior to the first blood draw
- •- Chronic illness (including, but not limited to, cardiac disorders, congenital heart disease, chronic lung disease, renal disorders, auto-immune disorders, diabetes, psychomotor diseases, and know congenital or genetic diseases) that, in the opinion of the Investigator, is at a stage where it might interfere with study conduct or completion
- •- Any condition which, in the opinion of the Investigator, might interfere with the evaluation of the study objectives
- •- In an emergency setting, or hospitalized involuntarily
- •- Moderate or severe acute illness/infection (according to Investigator judgment) on the day of vaccination or febrile illness (temperature = 38.0°C / = 100.4°F). A prospective participant should not be included in the study until the condition has resolved or until 3 days after the febrile event has resolved
- •- Identified as a natural or adopted child of the Investigator or employee with direct involvement in the proposed study
- •Specifically for toddlers
- •- Receipt of any vaccine in the 4 weeks preceding the study vaccination or planned receipt of any vaccine from enrollment through the last blood sampling Visit (Visit 2), except for influenza vaccination, which may be received at least 2 weeks before or 2 weeks after any study vaccination. This exception includes monovalent pandemic influenza vaccines and multivalent influenza vaccines
- •- Receipt of immune globulins, blood or blood-derived products in the past 3 months
- •- Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
- •- History of diphtheria, tetanus, pertussis, poliomyelitis, and/or H. influenzae type b infection or disease
- •Specifically for infants
- •- Receipt of any vaccine in the 4 weeks preceding the study vaccination or planned receipt of any vaccine from enrollment through t
研究者
相似试验
已完成
不适用
Inmunogenicity-PCV-Carriage-Venezuelan High Risk ChildreInfection Prophylaxis of Streptococcus pneumoniaeRPCEC00000150Servicio Autónomo Instituto de Biomedicina110
进行中（未招募）
1 期
Immunogenicity of conjugate pneumococcal vaccine (Prevenar) in patients with ataxia -telangiectasia (AT) including a randomised study of one versus two doses of vaccine. - Immunogenicity of Prevenar in Ataxia telangiectasiaEUCTR2005-004122-70-GBGreat Ormond Street Hospital30
招募中
2 期
Immunogenicity and Safety of a 13-valent pneumococcal conjugate vaccine in paediatric oncology patientspaediatric malignancyCancer - Children's - BrainCancer - Children's - Leukaemia & LymphomaCancer - Children's - OtherACTRN12613000264785Te-Yu Hung100
进行中（未招募）
不适用
Immune response to pneumococcal conjugate vaccine in adults receiving hepatitis A vaccine concomitantly18 years old or older volunteers with general good healthEUCTR2012-003484-22-FIHelsinki University Central Hospital600
进行中（未招募）
不适用
Immune response to pneumococcal conjugate vaccine in adults receiving hepatitis A vaccine concomitantlyEUCTR2012-003484-22-SEHelsinki University Central Hospital300